875 related articles for article (PubMed ID: 14749145)
21. [Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension].
Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Ritz E
Dtsch Med Wochenschr; 2004 Jan; 129(1-2):13-8. PubMed ID: 14703575
[TBL] [Abstract][Full Text] [Related]
22. Losartan in diabetic nephropathy.
Perico N; Ruggenenti P; Remuzzi G
Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
[TBL] [Abstract][Full Text] [Related]
23. A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.
Palmer AJ; Valentine WJ; Tucker DM; Ray JA; Roze S; Annemans L; Lapuerta P; Chen R; Gabriel S; Carita P; Rodby RA; de Zeeuw D; Parving HH; Laville M
Curr Med Res Opin; 2006 Nov; 22(11):2095-100. PubMed ID: 17076969
[TBL] [Abstract][Full Text] [Related]
24. Recommendations for the management of special populations: renal disease in diabetes.
Raij L
Am J Hypertens; 2003 Nov; 16(11 Pt 2):46S-49S. PubMed ID: 14625161
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes.
Eberhard R; Dikow R
Ann Med; 2002; 34(7-8):507-13. PubMed ID: 12553490
[TBL] [Abstract][Full Text] [Related]
26. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D
J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317
[TBL] [Abstract][Full Text] [Related]
27. [Clinical and health economic implications of early treatment with irbesartan of patients with type 2 diabetes mellitus, hypertension and nephropathy].
Palmer AJ; Roze S; Rodby RA; Valentine WJ; Ritz E; Lehnert H
Dtsch Med Wochenschr; 2006 Aug; 131(31-32):1721-6. PubMed ID: 16868875
[TBL] [Abstract][Full Text] [Related]
28. The cost-effectiveness of losartan in type 2 diabetics with nephropathy in Switzerland--an analysis of the RENAAL study.
Szucs TD; Sandoz MS; Keusch GW
Swiss Med Wkly; 2004 Aug; 134(31-32):440-7. PubMed ID: 15389347
[TBL] [Abstract][Full Text] [Related]
29. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.
Palmer AJ; Valentine WJ; Ray JA
Int J Clin Pract; 2007 Oct; 61(10):1626-33. PubMed ID: 17877649
[TBL] [Abstract][Full Text] [Related]
30. Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial.
McMullan CJ; Lambers Heerspink HJ; Parving HH; Dwyer JP; Forman JP; de Zeeuw D
Am J Kidney Dis; 2014 Nov; 64(5):714-22. PubMed ID: 25064674
[TBL] [Abstract][Full Text] [Related]
31. Irbesartan delays progression of nephropathy as measured by estimated glomerular filtration rate: post hoc analysis of the Irbesartan Diabetic Nephropathy Trial.
Evans M; Bain SC; Hogan S; Bilous RW;
Nephrol Dial Transplant; 2012 Jun; 27(6):2255-63. PubMed ID: 22172728
[TBL] [Abstract][Full Text] [Related]
32. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL.
de Zeeuw D; Ramjit D; Zhang Z; Ribeiro AB; Kurokawa K; Lash JP; Chan J; Remuzzi G; Brenner BM; Shahinfar S
Kidney Int; 2006 May; 69(9):1675-82. PubMed ID: 16572114
[TBL] [Abstract][Full Text] [Related]
33. The value of irbesartan in the management of hypertension.
Bramlage P; Durand-Zaleski I; Desai N; Pirk O; Hacker C
Expert Opin Pharmacother; 2009 Aug; 10(11):1817-31. PubMed ID: 19601700
[TBL] [Abstract][Full Text] [Related]
34. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.
Palmer AJ; Annemans L; Roze S; Lamotte M; Rodby RA; Cordonnier DJ
Nephrol Dial Transplant; 2003 Oct; 18(10):2059-66. PubMed ID: 13679481
[TBL] [Abstract][Full Text] [Related]
35. Bilirubin and progression of nephropathy in type 2 diabetes: a post hoc analysis of RENAAL with independent replication in IDNT.
Riphagen IJ; Deetman PE; Bakker SJ; Navis G; Cooper ME; Lewis JB; de Zeeuw D; Lambers Heerspink HJ
Diabetes; 2014 Aug; 63(8):2845-53. PubMed ID: 24677717
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
Keane WF; Lyle PA;
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
[TBL] [Abstract][Full Text] [Related]
37. A clinical trial in type 2 diabetic nephropathy.
Lewis EJ; Hunsicker LG; Rodby RA;
Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S191-4. PubMed ID: 11576953
[TBL] [Abstract][Full Text] [Related]
38. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.
Bakris GL; Weir MR; Shanifar S; Zhang Z; Douglas J; van Dijk DJ; Brenner BM;
Arch Intern Med; 2003 Jul; 163(13):1555-65. PubMed ID: 12860578
[TBL] [Abstract][Full Text] [Related]
39. Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database.
Packham DK; Alves TP; Dwyer JP; Atkins R; de Zeeuw D; Cooper M; Shahinfar S; Lewis JB; Lambers Heerspink HJ
Am J Kidney Dis; 2012 Jan; 59(1):75-83. PubMed ID: 22051245
[TBL] [Abstract][Full Text] [Related]
40. Angiotensin II receptor blockers and nephropathy trials.
Bloomgarden ZT
Diabetes Care; 2001 Oct; 24(10):1834-8. PubMed ID: 11574450
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
